Role of clotting factors and fibrin structure in predisposition to atherothrombotic disease

Expert Review of Cardiovascular Therapy

Volumn 3, Issue 6, 2005, Pages 1047-1059

  Ajjan, Ramzi A ^a   Grant, Peter J ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Atherothrombosis; Clot structure; Coagulation factors; Coronary artery disease; Factor XIII; Fibrinogen

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA 2 ANTIPLASMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BINDING PROTEIN; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 13B; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESTROGEN; FIBRIC ACID DERIVATIVE; FIBRIN; FIBRINOGEN; FLUINDOSTATIN; FONDAPARINUX; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; MONOCLONAL ANTIBODY; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR; SIMVASTATIN; SULFONYLUREA DERIVATIVE; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; XIMELAGATRAN;

ALCOHOL CONSUMPTION; AMINO ACID SUBSTITUTION; ARTERY THROMBOSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CORONARY ARTERY OBSTRUCTION; CORONARY RISK; CORRELATION ANALYSIS; DIABETES MELLITUS; DIET; DISEASE ASSOCIATION; ENVIRONMENTAL FACTOR; ETHNIC DIFFERENCE; EXERCISE; FIBRIN CLOT; GENE DELETION; GENE INSERTION; GENE LINKAGE DISEQUILIBRIUM; GENE MUTATION; GENETIC DISORDER; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HEART INFARCTION; HEART PROTECTION; HEREDITY; HETEROZYGOSITY; HIGH RISK PATIENT; HORMONE SUBSTITUTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MORBIDITY; MORTALITY; NONHUMAN; PERIPHERAL VASCULAR DISEASE; PROMOTER REGION; PROTEIN CROSS LINKING; PROTEIN DEGRADATION; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SMOKING; STRUCTURE ANALYSIS; THROMBOGENESIS;

ARTERIOSCLEROSIS; BLOOD COAGULATION FACTORS; DISEASE SUSCEPTIBILITY; FIBRIN; HUMANS; MOLECULAR STRUCTURE; THROMBOSIS;

EID: 28644432165     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.3.6.1047     Document Type: Review

References (104)

1. Greenberg CS, Lai TS, Ariens RAS, Weisel JW, Grant PJ. Biology and disorders of fibrinogen and Factor XIII. In: Blood-principles and practice of hematology. Handin RI, Lux SE, Stossel TO (Eds.). Lippincott Williams & Wilkins, 1225-1248 (2001).
2. Meh DA, Siebenlist KR, Brennan SO, Holyst T, Mosesson MW. The amino acid sequence in fibrin responsible for high affinity thrombin binding. Thromb. Haemost. 85, 470-474 (2001).
3. Siebenlist KR, Meh DA, Mosesson MW. Protransglutaminase (Factor XIII) mediated crosslinking of fibrinogen and fibrin. Thromb. Haemost. 86, 1221-1228 (2001).
4. Cooper AV, Standeven KF, Ariens RA. Fibrinogen γ-chain splice variant-γ alters fibrin formation and structure. Blood 102, 535-540 (2003).
5. Lovely RS, Falls LA, Al Mondhiry HA et al. Association of γA/γ′ fibrinogen levels and coronary artery disease. Thromb. Haemost. 88, 26-31 (2002).
6. Norris LA. Blood coagulation. Best Pract. Res. Clin. Obstet. Gynaecol. 17, 369-383 (2003).
7. Gaffney PJ. Fibrin degradation products. A review of structures found in vitro and in vivo. Ann. NY Acad. Sci. 936, 594-610 (2001).
8. Medved L, Nieuwenhuizen W. Molecular mechanisms of initiation of fibrinolysis by fibrin. Thromb. Haemost. 89, 409-419 (2003).
9. Fatah K, Silveira A, Tornvall P et al. Proneness to formation of tight and rigid fibrin gel structures in men with myocardial infarction at a young age. Thromb. Haemost. 76, 535-540 (1996).
10. Fatah K, Hamsten A, Blomback B, Blomback M. Fibrin gel network characteristics and coronary heart disease: relations to plasma fibrinogen concentration, acute phase protein, serum lipoproteins and coronary atherosclerosis. Thromb. Haemost. 68, 130-135 (1992).
11. Jorneskog G, Egberg N, Fagrell B et al. Altered properties of the fibrin gel structure in patients with IDDM. Diabetologia 39, 1519-1523 (1996).
12. Shats EA, Nair CH, Dhall DP. Interaction of endothelial cells and fibroblasts with modified fibrin networks: role in atherosclerosis. Atherosclerosis 129, 9-15 (1997).
13. Collet JP, Park D, Lesty C et al. Influence of fibrin network conformation and fibrin fiber diameter on fibrinolysis speed: dynamic and structural approaches by confocal microscopy. Arterioscler. Thromb. Vasc. Biol. 20, 1354-1361 (2000).
14. Blomback B. Fibrinogen structure, activation, polymerization and fibrin gel structure. Thromb. Res. 75, 327-328 (1994).
15. Koenig W. Fibrin(ogen) in cardiovascular disease: an update. Thromb. Haemost. 89, 601-609 (2003).
16. Meade TW, Mellows S, Brozovic M et al. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 2, 533-537 (1986).
17. Collet JP, Soria J, Mirshahi M et al. Dusart syndrome: a new concept of the relationship between fibrin clot architecture and fibrin clot degradability: hypofibrinolysis related to an abnormal clot structure. Blood 82, 2462-2469 (1993).
18. Ariens RA, de Lange M, Snieder H et al. Activation markers of coagulation and fibrinolysis in twins: heritability of the prethrombotic state. Lancet 359, 667-671 (2002).
19. de Lange M, Snieder H, Ariens RA, Spector TD, Grant PJ. The genetics of haemostasis: a twin study. Lancet 357, 101-105 (2001).
20. Peetz D, Victor A, Adams P et al. Genetic and environmental influences on the fibrinolytic system: a twin study. Thromb. Haemost. 92, 344-351 (2004).
21. Mills JD, Ariens RA, Mansfield MW, Grant PJ. Altered fibrin clot structure in the healthy relatives of patients with premature coronary artery disease. Circulation 106, 1938-1942 (2002).
22. Yu S, Sher B, Kudryk B, Redman CM. Fibrinogen precursors. Order of assembly of fibrinogen chains. J. Biol. Chem. 259, 10574-10581 (1984).
23. Grant PJ, Humphries SE. Genetic determinants of arterial thrombosis. Baillieres Best Pract. Res. Clin. Haematol. 12, 505-532 (1999).
24. Green FR. Fibrinogen polymorphisms and atherothrombotic disease. Ann. NY Acad. Sci. 936, 549-559 (2001).
25. Iacoviello L, Vischetti M, Zito F, Benedetta DM. Genes encoding fibrinogen and cardiovascular risk. Hypertension 38, 1199-1203 (2001).
26. Grant PJ. The genetics of atherothrombotic disorders: a clinician's view. J. Thromb. Haemost. 1, 1381-1390 (2003).
27. Standeven KF, Grant PJ, Carter AM et al. Functional analysis of the fibrinogen A αThR312Ala polymorphism: effects on fibrin structure and function. Circulation 107, 2326-2330 (2003).
28. Carter AM, Catto AJ, Grant PJ. Association of the α-fibrinogen ThR312Ala polymorphism with poststroke mortality in subjects with atrial fibrillation. Circulation 99, 2423-2426 (1999).
29. Carter AM, Catto AJ, Kohler HP et al. α-fibrinogen ThR312Ala polymorphism and venous thromboembolism. Blood 96, 1177-1179 (2000).
30. Lim BC, Ariens RA, Carter AM, Weisel JW, Grant PJ. Genetic regulation of fibrin structure and function: complex gene-environment interactions may modulate vascular risk. Lancet 361, 1424-1431 (2003).
31. Maghzal GJ, Brennan SO, George PM. Fibrinogen Bβ polymorphisms do not directly contribute to an altered in vitro clot structure in humans. Thromb. Haemost. 90, 1021-1028 (2003).
32. Behague I, Poirier O, Nicaud V et al. β-fibrinogen gene polymorphisms are associated with plasma fibrinogen and coronary artery disease in patients with myocardial infarction. The ECTIM study. Etude Cas-Temoins sur l'Infarctus du Myocarde. Circulation 93, 440-449 (1996).
33. Carter AM, Catto AJ, Bamford JM, Grant PJ. Gender-specific associations of the fibrinogen Bβ 448 polymorphism, fibrinogen levels, and acute cerebrovascular disease. Arterioscler. Thromb. Vasc. Biol. 17, 589-594 (1997).
34. Attie-Castro FA, Zago MA, Lavinha J et al. Ethnic heterogeneity of the Factor XIII Val34Leu polymorphism. Thromb. Haemost. 84, 601-603 (2000).
35. Kohler HP, Stickland MH, Ossei-Gerning N et al. Association of a common polymorphism in the Factor XIII gene with myocardial infarction. Thromb. Haemost. 79, 8-13 (1998).
36. Ariens RA, Philippou H, Nagaswami C et al. The Factor XIII V34L polymorphism accelerates thrombin activation of Factor XIII and affects cross-linked fibrin structure. Blood 96, 988-995 (2000).
37. Ariens RA, Lai TS, Weisel JW, Greenberg CS, Grant PJ. Role of Factor XIII in fibrin clot formation and effects of genetic polymorphisms. Blood 100, 743-754 (2002).
38. Kobbervig C, Williams E. FXIII polymorphisms, fibrin clot structure and thrombotic risk. Biophys. Chem. 112, 223-228 (2004).
39. Folsom AR. Hemostatic risk factors for atherothrombotic disease: an epidemiologic view. Thromb. Haemost. 86, 366-373 (2001).
40. Humphries SE, Lane A, Dawson S, Green FR. The study of gene-environment interactions that influence thrombosis and fibrinolysis. Genetic variation at the loci for Factor VII and plasminogen activator inhibitor-1. Arch. Pathol. Lab. Med. 116, 1322-1329 (1992).
41. Zhan M, Zhou Y, Han ZC. No association of the plasminogen activator inhibitor-1 promoter 4G/5G polymorphism with inhibitor level during basal transcription in vitro. Int. J. Hematol. 79, 400-404 (2004).
42. Hoekstra T, Geleijnse JM, Schouten EG, Kluft C. Plasminogen activator inhibitor-type 1: its plasma determinants and relation with cardiovascular risk. Thromb. Haemost. 91, 861-872 (2004).
43. Iacoviello L, Burzotta F, Di Castelnuovo A et al. The 4G/5G polymorphism of PAI-1 promoter gene and the risk of myocardial infarction: a meta-analysis. Thromb. Haemost. 80, 1029-1030 (1998).
44. Hammar N, Kaprio J, Hagstrom U et al. Migration and mortality: a 20 year follow-up of Finnish twin pairs with migrant co-twins in Sweden. J. Epidemiol. Community Health 56, 362-366 (2002).
45. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA 241, 2035-2038 (1979).
46. Wei M, Gaskill SP, Haffner SM, Stern MP. Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality. The San Antonio Heart Study. Diabetes Care 21, 1167-1172 (1998).
47. Dunn EJ, Ariens RA. Fibrinogen and fibrin clot structure in diabetes. Herz 29, 470-479 (2004).
48. Fanghanel G, Silva U, Sanchez-Reyes L et al. Effects of metformin on fibrinogen levels in obese patients with Type 2 diabetes. Rev. Invest. Clin. 50, 389-394 (1998).
49. Cefalu WT, Schneider DJ, Carlson HE et al. Effect of combination glipizide GITS/metformin on fibrinolytic and metabolic parameters in poorly controlled Type 2 diabetic subjects. Diabetes Care 25, 2123-2128 (2002).
50. Yudkin JS, Panahloo A, Stehouwer C et al. The influence of improved glycaemic control with insulin and sulphonylureas on acute phase and endothelial markers in Type II diabetic subjects. Diabetologia 43, 1099-1106 (2000).
51. Hammer MR, John PN, Flynn MD, Bellingham AJ, Leslie RD. Glycated fibrinogen: a new index of short-term diabetic control. Ann. Clin. Biochem. 26 (Pt. 1), 58-62 (1989).
52. Dunn E, Ariens RAS, Grant PJ. The influence of Type 2 diabetes on clot structure and function. Diabetologia 48(6), 1198-1206 (2005).
53. Jorneskog G, Hansson LO, Wallen NH, Yngen M, Blomback M. Increased plasma fibrin gel porosity in patients with Type I diabetes during continuous subcutaneous insulin infusion. J. Thromb. Haemost. 1, 1195-1201 (2003).
54. Rosenson RS, Koenig W. Utility of inflammatory markers in the management of coronary artery disease. Am. J. Cardiol. 92, i10-i18 (2003).
55. Speidl WS, Zeiner A, Nikfardjam M et al. An increase of C-reactive protein is associated with enhanced activation of endogenous fibrinolysis at baseline but an impaired endothelial fibrinolytic response after venous occlusion. J. Am. Coll. Cardiol. 45, 30-34 (2005).
56. Devaraj S, Xu DY, Jialal I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation 107, 398-404 (2003).
57. Shats-Tseytlina EA, Nair CH, Dhall DP. Complement activation: a new participant in the modulation of fibrin gel characteristics and the progression of atherosclerosis? Blood Coagul. Fibrinolysis 5, 529-535 (1994).
58. Christiansen MS, Hommel E, Magid E, Feldt-Rasmussen B. Orosomucoid in urine is a powerful predictor of cardiovascular mortality in normoalbuminuric patients with Type 2 diabetes at five years of follow-up. Diabetologia 48, 386-393 (2005).
59. Esmon CT. Inflammation and thrombosis. J. Thromb. Hoemost. 1, 1343-1348 (2003).
60. Veldman FJ, Nair CH, Vorster HH et al. Dietary pectin influences fibrin network structure in hypercholesterolaemic subjects. Thromb. Res. 86, 183-196 (1997).
61. de Lange DW, van de WA. Drink to prevent: review on the cardioprotective mechanisms of alcohol and red wine polyphenols. Semin. Vasc. Med. 4, 173-186 (2004).
62. Chrysohoou C, Panagiotakos DB, Pitsavos C, Das UN, Stefanadis C. Adherence to the Mediterranean diet attenuates inflammation and coagulation process in healthy adults: The ATTICA Study. J. Am. Coll. Cardiol. 44, 152-158 (2004).
63. Oosthuizen W, Vorster HH, Jerling JC et al. Both fish oil and olive oil lowered plasma fibrinogen in women with high baseline fibrinogen levels. Thromb. Haemost. 72, 557-562 (1994).
64. de Gaetano G, Di Castelnuovo A, Donati MB, Iacoviello L. The Mediterranean lecture: wine and thrombosis - from epidemiology to physiology and back. Pathophysiol. Haemost. Thromb. 33, 466-471 (2003).
65. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA 279, 1477-1482 (1998).
66. Connelly JB, Cooper JA, Meade TW. Strenuous exercise, plasma fibrinogen, and Factor VII activity. Br. Heart J. 67, 351-354 (1992).
67. Gibbs CR, Blann AD, Edmunds E, Watson RD, Lip GY. Effects of acute exercise on hemorheological, endothelial, and platelet markers in patients with chronic heart failure in sinus rhythm. Clin. Cardiol. 24, 724-729 (2001).
68. Iso H, Shimamoto T, Sato S et al. Passive smoking and plasma fibrinogen concentrations. Am. J. Epidemiol. 144, 1151-1154 (1996).
69. de Maat MP. Effects of diet, drugs, and genes on plasma fibrinogen levels. Ann. NY Acad. Sci. 936, 509-521 (2001).
70. Juhan-Vague I, Valadier J, Alessi MC et al. Deficient t-PA release and elevated PA inhibitor levels in patients with spontaneous or recurrent deep venous thrombosis. Thromb. Haemost. 57, 67-72 (1987).
71. Tekin A, Tekin G, Guzelsoy D et al. Effects of atorvastatin (10 mg) on hemostatic and inflammatory parameters in hyperlipidemic patients with angiographically proven coronary artery disease. Am. J. Cardiol. 94, 206-209 (2004).
72. Mussoni L, Mannucci L, Sirtori M et al. Hypertriglyceridemia and regulation of fibrinolytic activity. Arterioscler. Thromb. 12, 19-27 (1992).
73. Latron Y, Chautan M, Anfosso F et al. Stimulating effect of oxidized low density lipoproteins on plasminogen activator inhibitor-1 synthesis by endothelial cells. Arterioscler. Thromb. 11, 1821-1829 (1991).
74. Bjornsson TD, Schneider DE, Berger H Jr. Aspirin acetylates fibrinogen and enhances fibrinolysis. Fibrinolytic effect is independent of changes in plasminogen activator levels. J. Pharmacol. Exp. Ther. 250, 154-161 (1989).
75. Henschen-Edman AH. Fibrinogen non-inherited heterogeneity and its relationship to function in health and disease. Ann. NY Acad. Sci. 936, 580-593 (2001).
76. He S, Blomback M, Yoo G, Sinha R, Henschen-Edman AH. Modified clotting properties of fibrinogen in the presence of acetylsalicylic acid in a purified system. Ann. NY Acad. Sci. 936, 531-535 (2001).
77. Mazoyer E, Ripoll L, Boisseau MR, Droue L. How does ticlopidine treatment lower plasma fibrinogen? Thromb. Res. 75, 361-370 (1994).
78. Woodward M, Lowe GD, Francis LM, Rumley A, Cobbe SM. A randomized comparison of the effects of aspirin and clopidogrel on thrombotic risk factors and C-reactive protein following myocardial infarction: the CADET trial. J. Thromb. Haemost. 2, 1934-1940 (2004).
79. Undas A, Sydor WJ, Brummel K et al. Aspirin alters the cardioprotective effects of the Factor XIII Val34Leu polymorphism. Circulation 107, 17-20 (2003).
80. Fogari R, Zoppi A, Lazzari P et al. ACE inhibition but not angiotensin II antagonism reduces plasma fibrinogen and insulin resistance in overweight hypertensive patients. J. Cardiovasc. Pharmacol. 32, 616-620 (1998).
81. Makris TK, Stavroulakis GA, Krespi PG et al. Fibrinolytic/hemostatic variables in arterial hypertension: response to treatment with irbesartan or atenolol. Am. J. Hypertens. 13, 783-788 (2000).
82. Makris TK, Stavroulakis G, Papadopoulos DP et al. Eprosartan effect on fibrinolytic/hemostatic variables in arterial hypertension: a comparative study to losartan. Drugs Exp. Clin. Res. 30, 125-132 (2004).
83. Vaughan CJ, Gotto AM Jr. Update on statins: 2003. Circulation 110, 886-892 (2004).
84. Balk EM, Lau J, Goudas LC et al. Effects of statins on nonlipid serum markets associated with cardiovascular disease: a systematic review. Ann. Intern. Med. 139, 670-682 (2003).
85. Okopien B, Krysiak R, Madej A et al. Effect of simvastatin and fluvastatin on plasma fibrinogen levels in patients with primary hypercholesterolemia. Pol. J. Pharmacol. 56, 781-787 (2004).
86. Seljeflot I, Tonstad S, Hjermann I, Arnesen H. Improved fibrinolysis after 1-year treatment with HMG CoA reductase inhibitors in patients with coronary heart disease. Thromb. Res. 105, 285-290 (2002).
87. Dangas G, Badimon JJ, Smith DA et al. Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile. J. Am. Coll. Cardiol. 33, 1294-1304 (1999).
88. Elisaf M. Effects of fibrates on serum metabolic parameters. Curr. Med. Res. Opin. 18, 269-276 (2002).
89. Kockx M, Gervois PP, Poulain P et al. Fibrates suppress fibrinogen gene expression in rodents via activation of the peroxisome proliferator-activated receptor. Blood 93, 2991-2998 (1999).
90. Okopien B, Cwalina L, Lebek M et al. Effects of fibrates on plasma prothrombotic activity in patients with Type IIb dyslipidemia. Int. J. Clin. Pharmacol. Ther. 39, 551-557 (2001).
91. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with Type 2 diabetes (UKPDS 34). Lancet 352, 854-865 (1998).
92. Grant PJ. Beneficial effects of metformin on haemostasis and vascular function in man. Diabetes Metab. 29, 6S44-6S52 (2003).
93. Charles MA, Morange P, Eschwege E et al. Effect of weight change and metformin on fibrinolysis and the von Willebrand factor in obese nondiabetic subjects: the BIGPRO1 Study. Biguanides and the prevention of the risk of obesity. Diabetes Care 21, 1967-1972 (1998).
94. Standeven KF, Ariens RA, Whitaker P et al. The effect of dimethylbiguanide on thrombin activity, FXIII activation, fibrin polymerization, and fibrin clot formation. Diabetes 51, 189-197 (2002).
95. Dhall DP, Nair CH. Effects of gliclazide on fibrin network. J. Diabetes Complications 8, 231-234 (1994).
96. Psaty BM, Heckbert SR, Atkins D et al. A review of the association of estrogens and progestins with cardiovascular disease in postmenopausal women. Arch. Intern. Med. 153, 1421-1427 (1993).
97. Cushman M. Effects of hormone replacement therapy and estrogen receptor modulators on markers of inflammation and coagulation. Am. J. Cardiol. 90, F7-F10 (2002).
98. Giri S, Thompson PD, Taxel P et al. Oral estrogen improves serum lipids, homocysteine and fibrinolysis in elderly men. Atherosclerosis 137, 359-366 (1998).
99. Khan NS, Malhotra S. Effect of hormone replacement therapy on cardiovascular disease: current opinion. Expert. Opin. Pharmacother. 4, 667-674 (2003).
100. Gurewich V. Ximelagatran-promises and concerns. JAMA 293, 736-739 (2005).
101. Wallentin L, Wilcox RG, Weaver WD et al. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet 362, 789-797 (2003).
102. Bauer KA. Fondaparinux: a new synthetic and selective inhibitor of Factor Xa. Best. Pract. Res. Clin. Haematol. 17, 89-104 (2004).
103. Morrow DA, Murphy SA, McCabe CH et al. Potent inhibition of thrombin with a monoclonal antibody against tissue factor (Sunol-cH36): results of the PROXIMATE-TIMI 27 trial. Eur. Heart J. (2005).
104. Bianucci AM, Massarelli I, Chiellini F, Eidelman C, Chiellini E. Design of highly specific ligands of fibrin for therapeutic applications. J. Biomater. Sci. Polym. 15, 1203-1222 (2004).